香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Cutia Therapeutics 科笛集團 （於開曼群島註冊成立的有限公司） （股份代號：2487） 董事會會議召開日期 科笛集團（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於2025年8月28日 （星期四）舉行董事會會議，籍以（其中包括）考慮及批准本公司及其附屬公司截 至2025年6月30日止六個月的中期業績及其發佈，以及考慮建議派中期股息（如 有），並處理其他事項。 承董事會命 Cutia Therapeutics科笛集團 首席執行官兼執行董事 張樂樂 香港，2025年8月18日 於本公告日期，董事會包括(i)執行董事張樂樂女士及黃雨青先生；(ii)非執行董事 陳連勇博士、謝沁博士、黃瀟博士及楊雲霞女士；及(iii)獨立非執行董事鍾明杰 先生、陶德仁先生及葉曉翔先生。 ...

Core Viewpoint - The company is strategically positioning itself in the hair and skin care market by addressing unmet consumer needs and avoiding highly competitive segments, focusing on localized fat management, hair diseases and care, skin diseases and care, and epidermal anesthesia. Group 1: Hair Care - The demand for hair loss treatment is rapidly increasing in China, with the market previously dominated by minoxidil and oral finasteride, both having significant drawbacks [2] - The company exclusively represents the world's only topical finasteride spray, which enhances transdermal absorption and reduces side effects, with clinical efficacy comparable to oral finasteride [2] - The product CU-40102 is expected to be approved in June 2025 and commercialized by the end of the year, contributing significantly to the company's performance [2] Group 2: Skin Care - The acne treatment market in China is expanding, with traditional treatments facing issues like side effects and antibiotic resistance [2] - The company exclusively represents the world's only topical minocycline foam, overcoming absorption challenges through unique technology [2] - The product CU-10201 is anticipated to be approved in November 2024 and commercialized in the second half of 2025 [2] Group 3: Epidermal Anesthesia - The market for epidermal anesthesia is competitive, with the company aiming to innovate with its lidocaine-dinoprost combination [3] - The traditional lidocaine-dinoprost combination has been ineffective, leading to potential compliance risks for medical institutions [3] - The product CU-30101 has made significant progress and is expected to be the first approved lidocaine-dinoprost cream in China, with NDA submitted in July 2024 [3] Group 4: Localized Fat Management - The localized fat management market is in its early stages, with the company gradually enhancing its product line [3] - Most domestic lipolysis injections are based on deoxycholic acid, while the company is developing a differentiated product using mutated recombinant collagenase, promising improved safety and reduced pain [3] Investment Recommendation - The company has a comprehensive understanding of the skin and hair markets, with a diverse pipeline aligned with market demands, leading to a significant turnaround in performance as key products are launched [3] - Revenue projections for 2025-2027 are estimated at 494 million, 973 million, and 1.45 billion yuan, with net profits expected to shift from losses to a profit of 122 million yuan by 2027, corresponding to a PE ratio of 22 times [3]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5]. Core Views - The company is positioned as a platform in the hair and skin care sectors, focusing on unmet consumer needs and avoiding highly competitive domestic markets. It aims to commercialize products in localized fat management, hair diseases and care, skin diseases and care, and epidermal anesthesia [1][16]. - The company has a robust product pipeline, with significant growth expected from the commercialization of key products starting in 2025, including external minoxidil and finasteride [2][3]. Summary by Sections Company Overview - The company was founded in 2019 and has progressed through stages of product agency, introduction of differentiated products, and self-developed drugs. It focuses on four main areas: hair disease and care, skin disease and care, epidermal anesthesia, and localized fat management [16][22]. Financial Analysis - The company has shown rapid revenue growth, with a projected increase from 0.02 billion in 2021 to 2.80 billion in 2024, reflecting a CAGR of 415.8%. The hair care segment is a significant contributor, with revenue expected to exceed 1.6 billion in 2024 [22][24]. - The gross margin reached 51% in 2024, with a significant reduction in losses, indicating a trend towards profitability as revenues continue to grow [24][30]. Business Segments - The company is focused on addressing consumer pain points through a commercialized approach, with a product lineup that includes treatments for hair loss, skin conditions, and localized fat management. The first tier of products is primarily agency-based, while the second tier, including external minoxidil and finasteride, is set to launch in 2025 [32][33]. Hair Care Market - The hair care market in China is experiencing strong growth, with the number of individuals suffering from androgenetic alopecia reaching approximately 135.5 million in 2021. The market for hair loss treatments is projected to grow from 76.2 billion in 2017 to 144.3 billion by 2025, with a CAGR of 7.8% [36][39][40]. Skin Care Products - The company has secured approval for the world's first external minocycline foam, which is expected to be commercialized in 2025. This product addresses the growing demand in the acne treatment market, which is expanding significantly [3][4]. Epidermal Anesthesia - The company is developing a novel lidocaine-dinoprost combination product, which is anticipated to be the first approved in its category in China. This product aims to capture a significant share of the competitive market for epidermal anesthesia [3][4]. Localized Fat Management - The localized fat management segment is in its early development stages, with the company leveraging patented technology to create safer and more effective products for fat reduction [3][4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 科笛集团 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02487 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 ...

Group 1 - InnoCare (02577.HK) has partnered with NVIDIA to promote the large-scale implementation of the 800 VDC power architecture in AI data centers, which is designed for efficient power supply in megawatt-level computing infrastructure [1] - The 800 VDC system offers significant advantages over traditional 54V systems in terms of efficiency, thermal loss, and reliability, enabling a 100-1000 times increase in AI computing power [1] - The company's third-generation GaN devices provide a comprehensive power solution from 800V input to GPU terminals, covering a voltage range from 15V to 1200V [1] Group 2 - China Ruyi (00136.HK) received a strategic investment of HKD 3.9 billion from Wuji Capital to accelerate business expansion and acquisition plans [2] - LEPU Biopharma-B (02157.HK) has authorized T-cell connector technology with an upfront payment of USD 10 million and potential milestone payments of up to USD 850 million [2] - Sinopec Engineering (02386.HK) signed a front-end engineering design (FEED) contract for a large green hydrogen project in Yanbu, Saudi Arabia [2] Group 3 - Geely Automobile (00175.HK) reported total vehicle sales of 237,700 units in July, a year-on-year increase of 58% [3] - Great Wall Motors (02333.HK) achieved approximately 104,372 vehicle sales in July, reflecting a year-on-year growth of 14.34% [3] - NIO-SW (09866.HK) delivered 21,017 vehicles in July [3]

Group 1: Company Earnings - PCCW (00008.HK) reported a revenue of HKD 18.922 billion for the first half, a year-on-year increase of 7%, with a net loss of HKD 0.445 billion, narrowing by 4% [1] - Xinyi Solar (00968.HK) recorded a revenue of HKD 10.932 billion, a decrease of 6.5% year-on-year, with a net profit of HKD 0.746 billion, down 58.8% [2] - Xinyi Glass (00868.HK) had a revenue of HKD 9.821 billion, a year-on-year decrease of 9.7%, with a net profit of HKD 1.013 billion, down 59.6% [3] - Xinyi Energy (03868.HK) reported a revenue of HKD 1.21 billion, an increase of 7.7% year-on-year, with a net profit of HKD 0.45 billion, up 23.4% [4] - DTXS Silk Road Investment (02510.HK) issued a profit warning, expecting a mid-term net profit of approximately USD 180-200 million, a year-on-year increase of about 220% to 255% [5] - Lianhua Supermarket (00980.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 25-55 million [6] - Tibet Water Resources (01115.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 36 million, a year-on-year increase of about 300% [7] - Foton Motor (00420.HK) issued a profit warning, expecting a mid-term net profit of HKD 30.7 million, turning from loss to profit [8] - Hong Kong Travel (00308.HK) issued a profit warning, expecting a mid-term net loss exceeding HKD 70 million, turning from profit to loss [9] - Poly Property Group (00119.HK) issued a profit warning, expecting a mid-term net profit to decline by 40%-50% year-on-year [10] - Kefu Shan Group Holdings (08512.HK) issued a profit warning, expecting a mid-term net profit to decrease to approximately HKD 43-47 million [11] - Mobi Development (00947.HK) issued a profit warning, expecting a mid-term net loss of approximately HKD 32 million [12] - Changmao Biochemical Engineering (00954.HK) issued a profit warning, expecting a mid-term net loss of approximately HKD 24-27 million [13] - Yunyou Holdings (00484.HK) issued a profit warning, expecting a mid-term net loss to increase to approximately HKD 21 million [14] - Weiya Li (00854.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 15-25 million, turning from loss to profit [15] Group 2: Automotive Sales - BYD Company (01211.HK) reported sales of approximately 2.4903 million new energy vehicles in the first seven months, a year-on-year increase of 27.35% [16] - Great Wall Motors (02333.HK) reported total vehicle sales of approximately 674,200 units in the first seven months, a year-on-year increase of 3.57% [17] - Li Auto (02015.HK) delivered 30,731 new vehicles in July [18] - Geely Automobile (00175.HK) reported total vehicle sales of 237,700 units in July, a year-on-year increase of approximately 58% [19] Group 3: Company News - Sinopec Engineering (02386.HK) signed a front-end engineering design (FEED) contract for a large green hydrogen project in Yanbu, Saudi Arabia, with a contract value expected to reach several billion USD [20] - InnoCare Pharma (02577.HK) partnered with NVIDIA to jointly promote the large-scale implementation of 800 VDC power architecture in AI data centers [21] - Zijin Mining (02899.HK) received parliamentary approval for the mining lease of the Akyem gold mine in Ghana, with a total transaction value of USD 1 billion [22] - Codex-B (02487.HK) received approval from the Hong Kong Department of Health for the listing of CU-40102 (topical finasteride spray) for the treatment of androgenetic alopecia [23] - Mixue Group (02097.HK) subscribed to a wealth management product from Pudong Development Bank, involving an investment of HKD 300 million [24] Group 4: Buyback Activities - Hang Seng Bank (00011.HK) repurchased 200,000 shares at a cost of approximately HKD 22.5922 million, with repurchase prices ranging from HKD 112.4 to 114.3 [25] - Vitasoy International (00345.HK) repurchased 1.844 million shares at a cost of approximately HKD 16.89 million, with repurchase prices ranging from HKD 9.14 to 9.17 [26]

Core Viewpoint - The company Codex-B (02487) has received approval from the Hong Kong government for its product CU-40102, a topical finasteride spray, for the treatment of androgenetic alopecia, marking a significant advancement following its approval by the National Medical Products Administration of China [1] Group 1: Product Approval and Features - CU-40102 is a topical formulation that inhibits the conversion of testosterone to dihydrotestosterone in the scalp, providing a treatment option for androgenetic alopecia [1] - Unlike oral finasteride, CU-40102 allows for precise application directly to the scalp, potentially reducing systemic exposure to the drug [1] Group 2: Market Implications - The approval of CU-40102 is a crucial step for the company in the hair disease and care sector, indicating extensive commercialization preparations in China [1] - This approval is expected to enhance the international presence of CU-40102, expanding its market reach and benefiting more patients suffering from androgenetic alopecia [1]

Core Viewpoint - The company Codex-B (02487) has received approval from the Hong Kong Department of Health for its product CU-40102, a topical finasteride spray for the treatment of androgenetic alopecia, marking a significant advancement following its approval by the National Medical Products Administration of China [1] Group 1: Product Details - CU-40102 is a topical formulation that inhibits the conversion of testosterone to dihydrotestosterone in the scalp, which is effective in treating androgenetic alopecia [1] - Unlike oral finasteride, CU-40102 allows for precise application directly to the scalp, potentially reducing systemic exposure to the drug [1] Group 2: Market Implications - The approval of CU-40102 is a crucial step for the company in the hair disease and care sector, as it prepares for extensive commercialization activities in China [1] - This approval will enhance the international positioning of CU-40102, expanding its market reach and benefiting more patients suffering from androgenetic alopecia [1]

Core Viewpoint - Codex-B (02487.HK) has received approval from the Hong Kong Department of Health for its topical finasteride spray, CU-40102, aimed at treating androgenetic alopecia, marking a significant advancement following its approval from the National Medical Products Administration of China [1] Group 1: Product Details - CU-40102 is a topical formulation that inhibits the conversion of testosterone to dihydrotestosterone in the scalp, providing a targeted treatment for androgenetic alopecia [1] - Unlike oral finasteride, CU-40102 allows for precise application on the scalp, potentially reducing systemic exposure to the drug [1] Group 2: Market Implications - The approval of CU-40102 is a crucial step for the company in the hair disease and care sector, indicating extensive commercialization preparations in China [1] - This approval is expected to enhance the international presence of CU-40102, expanding its market reach and benefiting more patients suffering from androgenetic alopecia [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Cutia Therapeutics 科笛集團 （於開曼群島註冊成立之有限公司） （股份代號：2487） 自願公告 CU-40102（外用非那雄胺噴霧劑） 獲得香港衛生署上市批准 本公告由科笛集團（「本公司」，連同其附屬公司統稱「本集團」）自願刊發，以告知 本公司股東及潛在投資者有關本集團最新業務發展資料。 本公司董事會（「董事會」）欣然宣佈，本集團的CU-40102（外用非那雄胺噴霧劑） 已獲得中華人民共和國（「中國」）香港特別行政區（「香港」）政府衛生署（「香港衛 生署」）上市批准，獲批的適應症為治療雄激素性脫髮。這是CU-40102繼取得中國 國家藥品監督管理局（「國家藥監局」）上市批准後又一重大進展。 非那雄胺作為特異性II型5α-還原酶競爭抑制劑抑制頭皮中睾酮轉化為雙氫睾酮， 可治療雄激素性脫髮。與口服非那雄胺不同，CU-40102的外用製劑便於患者將藥 物直接精確地塗抹在頭皮表面，與口服藥比 ...